Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.
0/5 보강
APA
Tedeschi A, Frustaci AM, et al. (2025). Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.. Leukemia, 39(12), 3060. https://doi.org/10.1038/s41375-025-02793-2
MLA
Tedeschi A, et al.. "Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.." Leukemia, vol. 39, no. 12, 2025, pp. 3060.
PMID
41184635 ↗